Please use this identifier to cite or link to this item:
Title: Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
Authors: Perez de Isla, Leopoldo
Alonso, Rodrigo
Watts, Gerald F
Mata, Nelva
Saltijeral Cerezo, Adriana
Muñiz, Ovidio
Fuentes, Francisco
Diaz-Diaz, José Luís
de Andrés, Raimundo
Zambón, Daniel
Rubio-Marin, Patricia
Barba-Romero, Miguel A
Saenz, Pedro
Sanchez Muñoz-Torrero, Juan F
Martinez-Faedo, Ceferino
Miramontes-Gonzalez, José P
Badimón, Lina
Mata, Pedro
SAFEHEART Investigators
Keywords: LDL-receptor mutations;cardiovascular disease;lipid-lowering therapy;low-density lipoprotein cholesterol
metadata.dc.subject.mesh: Adolescent
Anticholesteremic Agents
Cholesterol, LDL
Dose-Response Relationship, Drug
Drug Therapy, Combination
Follow-Up Studies
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipoproteinemia Type II
Middle Aged
Prospective Studies
Rosuvastatin Calcium
Time Factors
Treatment Outcome
Young Adult
Issue Date: 2016
Abstract: Familial hypercholesterolemia (FH) is the most common genetic disorder associated with premature atherosclerotic cardiovascular disease (ASCVD). There are sparse data on attainment of treatment targets; large registries that reflect real-life clinical practice can uniquely provide this information. We sought to evaluate the achievement of low-density lipoprotein cholesterol (LDL-C) treatment goals in FH patients enrolled in a large national registry. The SAFEHEART study (Spanish Familial Hypercholesterolemia Cohort Study) is a large, ongoing registry of molecularly defined patients with heterozygous FH treated in Spain. The attainment of guideline-recommended plasma LDL-C goals at entry and follow-up was investigated in relation to use of lipid-lowering therapy (LLT). The study recruited 4,132 individuals (3,745 of whom were ≥18 years of age); 2,752 of those enrolled were molecularly diagnosed FH cases. Mean follow-up was 5.1 ± 3.1 years; 71.8% of FH cases were on maximal LLT, and an LDL-C treatment target Despite the use of intensified LLT, many FH patients continue to experience high plasma LDL-C levels and, consequently, do not achieve recommended treatment targets. Type of LDL-receptor mutation, use of ezetimibe, coexistent diabetes, and ASCVD status can bear significantly on the likelihood of attaining LDL-C treatment goals.
metadata.dc.identifier.doi: 10.1016/j.jacc.2016.01.008
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.